Sanofi American Depositary Receipt (SNY)
Verona Pharma Is Launching Ohtuvayre, Although There Will Be Competition
VRNA received FDA approval for ensifentrine (Ohtuvayre) for the maintenance treatment of COPD on June 26. SNY/REGN's Dupixent represents a potential competitor. As do other drugs in development from SNY/REGN and GSK. Verona has the potential for further growth beyond the current approval, although in the near-term, initial sales seem likely to be a major determinant of the stock's direction.
German vaccine panel endorses Astra-Sanofi's RSV shot for infants
Germany's influential vaccine advisory panel said on Thursday all infants in the country should receive AstraZeneca and Sanofi's antibody therapy to protect them against the common respiratory infection RSV.
Sanofi-backed Formation Bio raises $372 million in late-stage funding round
AI-based drug developer Formation Bio said on Wednesday that it has raised $372 million in a late-stage funding round, with a significant participation from French drugmaker Sanofi.
Sanofi Looks To Sell $20B Icy Hot Division: Likely Bidders Include Advent, PAI Partners, Blackstone, CVC
Sanofi SA SNY is calling for initial bids for its $20 billion consumer health division.
Sanofi's Immunology Business Is Doing A Lot Of Heavy Lifting
Sanofi's shares have not fully recovered since announcing a business strategy change in October 2023, focusing on R&D investments and on separating its consumer healthcare business unit. The company's immunology business, led by Dupixent and other smaller products like Sarclisa, Beyfortus, and Altuviiio, is performing well. The immunology commercial portfolio and pipeline need to do a lot of the heavy lifting to maintain and improve Sanofi's growth profile.
Sanofi: A Leader In Life-Saving Vaccines And Treatments
In recent weeks, Sanofi has pleased investors with progress in the development of its pipeline of experimental drugs. On May 20, 2024, SNY announced additional results from a Phase 3 clinical trial that demonstrated Dupixent's greater efficacy in COPD treatment relative to my expectations. Dupixent sales amounted to 2.84 billion euros in the first three months of 2024, up 22.4% year-on-year.
FDA Delays Decision on Sanofi (SNY)-Regeneron Dupixent in COPD
Per the FDA, the data submitted by Sanofi (SNY)/Regeneron (REGN) for Dupixent in COPD indication constitutes a major amendment to its previously-submitted data. A final decision is expected by Sep 27.
FDA extends deadline, requests more data on Sanofi's Dupixent for treating 'smoker's lung'
French drugmaker Sanofi and its partner Regeneron said on Friday the U.S. Food and Drug Administration (FDA) requested additional analyses on the efficacy of Dupixent as an add-on treatment in certain patients 'smoker's lung', or COPD.
Sanofi's (SNY) Sarclisa sBLA Gets FDA's Priority Review Tag
The FDA grants priority review to Sanofi's (SNY) sBLA for the Sarclisa combination regimen for transplant-ineligible newly diagnosed multiple myeloma. A decision is due on Sep 27, 2024.
Bristol Myers, Sanofi liability in Hawaii Plavix case grows to $916 million
A judge in Hawaii on Tuesday ordered Bristol Myers Squibb and Sanofi to pay more than $916 million to the state for failing to warn non-white patients of health risks from its blood thinner Plavix, up from an earlier judgment of $834 million.
Sanofi (SNY) Signs Deal for AI-Powered Drug Development
Sanofi (SNY) inks collaboration deal with Formation Bio and OpenAI to build AI-powered software to advance drug development and create new medicines.
Sanofi partners with OpenAI: here's how it will mitigate AI related risks
Sanofi SA (EPA: SAN) is in focus today after teaming up with OpenAI to deploy artificial intelligence for drug development.
